Non-irritating concentrations recommended for skin testing by Europen network on Drug Allergy (ENDA)/European Academy of Allergy and Clinical Immunology (EAACI) [5] guidelines and AAIITO/SIAAIC [42] guidelines
| Excipients | Excipients-containing substances | Substance name | Concentration | ENDA/EAACI guidelines | AAIITO/SIAAIC guidelines | ||
|---|---|---|---|---|---|---|---|
| SPT | I.D. | SPT | I.D. | ||||
| PEG | PEG-containing vaccines | Comirnaty (PEG 2000) | 0.03 mg/0.03 mL | 1:1 | Starting at very low concentration | - | - |
| Moderna (PEG 2000) | 0.1 mg/0.5 mL | 1:1 | Starting at very low concentration | - | - | ||
| PEG-pure substances | PEG 300 | - | 1:1 | - | - | - | |
| PEG 400 | 1:1 | ||||||
| PEG 500 | 50% in water | ||||||
| PEG 2000 | 1%, 10%, and 50% in water | ||||||
| PEG 3000 | 10% in water | ||||||
| PEG 4000 | 50% in water | ||||||
| PEG 6000 | 50% in water | ||||||
| PEG-containing drugs | Depo-Medrol (methylprednisolone acetate, PEG 3350) | 40 mg/mL | 1:1 | 1:100 and 1:10 | 1:1 | 1:1,000, 1:100, and 1:10 | |
| Macrogol powder for oral solution (PEG 3350) | 170 mg/mL | 1:100, 1:10, and 1:1 | - | 1:100, 1:10, and 1:1 | - | ||
| PEG-derivatives | Polaxamer 407 (PEG 4000) | - | 10% in water | - | - | - | |
| PS80 | PS80-containing vaccines | AstraZeneca | 2.5 × 108 Inf.U/0.5 mL | 1:1 | - | - | - |
| Johnson & Johnson | ≥ 8.92 log10 Inf.U/0.5 mL | 1:1 | - | - | - | ||
| PS80-containing drugs | Kenacort (triamcinolone acetonide) | - | - | - | 1:1 | 1:100, 1:10, and 1:1 | |
| Optive plus eye drops (carboxymethylcellulose) | - | - | - | 1:1 | 1:100 and 1:10 | ||
| Tween 80 | - | - | 1%, 10%, and 20% in water | 0.1%, 1%, and 10% in saline | - | - | |
Inf.U: infectious units; I.D.: intradermal. -: No data available
Note. Adapted with permission from “Allergies and COVID-19 vaccines: an ENDA/EAACI position paper,” by Barbaud A, Garvey LH, Arcolaci A, Brockow K, Mori F, Mayorga C, et al. Allergy. 2022;77:2292–312 (https://onlinelibrary.wiley.com/doi/10.1111/all.15241). © 2022 EAACI and John Wiley and Sons A/S.